Ticker: AIM

AIM ImmunoTech Inc. (NYSE: AIM) is focused on the research and development of therapies for cancers and viral diseases, with its flagship product, Ampligen (rintatolimod), currently under clinical trials but not yet FDA-approved in the U.S. The financial results for the three months ending Mar...